Global Carcinoid Syndrome Diarrhea Treatment Market

Carcinoid Syndrome Diarrhea Treatment Comprehensive Study by End User (Hospitals and Clinics, Cancer Research Institutes, Others), Treatment (Chemotherapy, Oral Therapy, Somatostatin Analog (SSA) Therapy, Others) Players and Region - Global Market Outlook to 2026

Carcinoid Syndrome Diarrhea Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Carcinoid syndrome mostly occurs in a patients sufferings from metastatic neuroendocrine tumors. These are slow growing tumors and occur in the gastrointestinal tract result in chronic diarrhea. This causes weight loss, dehydration, malnutrition, and electrolyte imbalance which can be controlled by reducing the production of serotonin hormone. Increasing research to developed advanced treatments for Carcinoid syndrome Diarrhea expected to drive the market over the forecasted period.This growth is primarily driven by Development of Non-Surgical Treatment Such As Embolization, Somatostatin Analogs, and Others. and Emphasizing On Orphan Drugs for Carcinoid Syndrome Treatment.

Globally, a noticeable market trend is evident Treating Carcinoid Tumors by Biological Therapy with Interferon Alfa Drug . Major Players, such as Ipsen Biopharmaceuticals Inc. (France), Lexicon Pharmaceuticals, Inc. (United States), Novartis International AG (Switzerland), Pharmascience Inc. (Canada), Omega Laboratories Ltd. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (United States), Sirtex Medical Limited (Australia), BTG International Ltd. (United Kingdom) and Starpharma Holdings Limited (Australia) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

16 October 2018, Health Canada approves XERMELOTM treatment for adults whose refractory carcinoid syndrome diarrhea previously controlled by somatostatin analogue therapy alone.

Regulatory Insights:
Recently in 2018, “Food and Drug Administration (FDA) approved a new targeted treatment, lutetium Lu 177 dotatate, for adult patients with advanced NETs that affect the pancreas or gastrointestinal tract, known as GEP-NETs. Lutetium Lu 177 dotatate is the first radioactive drug approved to treat these rare cancers.”

Market Drivers
  • Development of Non-Surgical Treatment Such As Embolization, Somatostatin Analogs, and Others.
  • Emphasizing On Orphan Drugs for Carcinoid Syndrome Treatment

Market Trend
  • Treating Carcinoid Tumors by Biological Therapy with Interferon Alfa Drug
  • Development of New Drugs to Treat Carcinoid Syndrome

Restraints
  • Low Availability of Therapeutic For Treatment of Carcinoid Syndrome

Opportunities
Advancement in Therapies for Carcinoid Syndrome Diarrhea Treatment
Challenges
Lack of Healthcare Infrastructure in Developing Economies and Reducing Adverse Effect of Treatment Such As Flu, Fatigue, and Others

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Carcinoid Syndrome Diarrhea Treatment Study Sheds Light on
— The Carcinoid Syndrome Diarrhea Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Carcinoid Syndrome Diarrhea Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Carcinoid Syndrome Diarrhea Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By End User
  • Hospitals and Clinics
  • Cancer Research Institutes
  • Others

By Treatment
  • Chemotherapy
  • Oral Therapy
  • Somatostatin Analog (SSA) Therapy
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Development of Non-Surgical Treatment Such As Embolization, Somatostatin Analogs, and Others.
      • 3.2.2. Emphasizing On Orphan Drugs for Carcinoid Syndrome Treatment
    • 3.3. Market Challenges
      • 3.3.1. Lack of Healthcare Infrastructure in Developing Economies
      • 3.3.2. Reducing Adverse Effect of Treatment Such As Flu, Fatigue, and Others
    • 3.4. Market Trends
      • 3.4.1. Treating Carcinoid Tumors by Biological Therapy with Interferon Alfa Drug
      • 3.4.2. Development of New Drugs to Treat Carcinoid Syndrome
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Carcinoid Syndrome Diarrhea Treatment, by End User , Treatment and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Carcinoid Syndrome Diarrhea Treatment (Value)
      • 5.2.1. Global Carcinoid Syndrome Diarrhea Treatment by: Treatment (Value)
        • 5.2.1.1. Chemotherapy
        • 5.2.1.2. Oral Therapy
        • 5.2.1.3. Somatostatin Analog (SSA) Therapy
        • 5.2.1.4. Others
      • 5.2.2. Global Carcinoid Syndrome Diarrhea Treatment Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Taiwan
          • 5.2.2.2.6. Australia
          • 5.2.2.2.7. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
    • 5.3. Global Carcinoid Syndrome Diarrhea Treatment (Price)
  • 6. Carcinoid Syndrome Diarrhea Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ipsen Biopharmaceuticals Inc. (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Lexicon Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis International AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pharmascience Inc. (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Omega Laboratories Ltd. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan N.V. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sirtex Medical Limited (Australia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. BTG International Ltd. (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Starpharma Holdings Limited (Australia)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Carcinoid Syndrome Diarrhea Treatment Sale, by End User , Treatment and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Carcinoid Syndrome Diarrhea Treatment (Value)
      • 7.2.1. Global Carcinoid Syndrome Diarrhea Treatment by: Treatment (Value)
        • 7.2.1.1. Chemotherapy
        • 7.2.1.2. Oral Therapy
        • 7.2.1.3. Somatostatin Analog (SSA) Therapy
        • 7.2.1.4. Others
      • 7.2.2. Global Carcinoid Syndrome Diarrhea Treatment Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Taiwan
          • 7.2.2.2.6. Australia
          • 7.2.2.2.7. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
    • 7.3. Global Carcinoid Syndrome Diarrhea Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Carcinoid Syndrome Diarrhea Treatment: by Treatment(USD Million)
  • Table 2. Carcinoid Syndrome Diarrhea Treatment Chemotherapy , by Region USD Million (2015-2020)
  • Table 3. Carcinoid Syndrome Diarrhea Treatment Oral Therapy , by Region USD Million (2015-2020)
  • Table 4. Carcinoid Syndrome Diarrhea Treatment Somatostatin Analog (SSA) Therapy , by Region USD Million (2015-2020)
  • Table 5. Carcinoid Syndrome Diarrhea Treatment Others , by Region USD Million (2015-2020)
  • Table 6. South America Carcinoid Syndrome Diarrhea Treatment, by Country USD Million (2015-2020)
  • Table 7. South America Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 8. South America Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 9. Brazil Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 10. Brazil Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 11. Argentina Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 12. Argentina Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 13. Rest of South America Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 14. Rest of South America Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 15. Asia Pacific Carcinoid Syndrome Diarrhea Treatment, by Country USD Million (2015-2020)
  • Table 16. Asia Pacific Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 17. Asia Pacific Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 18. China Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 19. China Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 20. Japan Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 21. Japan Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 22. India Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 23. India Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 24. South Korea Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 25. South Korea Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 26. Taiwan Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 27. Taiwan Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 28. Australia Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 29. Australia Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 30. Rest of Asia-Pacific Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 31. Rest of Asia-Pacific Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 32. Europe Carcinoid Syndrome Diarrhea Treatment, by Country USD Million (2015-2020)
  • Table 33. Europe Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 34. Europe Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 35. Germany Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 36. Germany Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 37. France Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 38. France Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 39. Italy Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 40. Italy Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 41. United Kingdom Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 42. United Kingdom Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 43. Netherlands Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 44. Netherlands Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 45. Rest of Europe Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 46. Rest of Europe Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 47. MEA Carcinoid Syndrome Diarrhea Treatment, by Country USD Million (2015-2020)
  • Table 48. MEA Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 49. MEA Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 50. Middle East Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 51. Middle East Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 52. Africa Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 53. Africa Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 54. North America Carcinoid Syndrome Diarrhea Treatment, by Country USD Million (2015-2020)
  • Table 55. North America Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 56. North America Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 57. United States Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 58. United States Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 59. Canada Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 60. Canada Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 61. Mexico Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2015-2020)
  • Table 62. Mexico Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2015-2020)
  • Table 63. Company Basic Information, Sales Area and Its Competitors
  • Table 64. Company Basic Information, Sales Area and Its Competitors
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Carcinoid Syndrome Diarrhea Treatment: by Treatment(USD Million)
  • Table 74. Carcinoid Syndrome Diarrhea Treatment Chemotherapy , by Region USD Million (2021-2026)
  • Table 75. Carcinoid Syndrome Diarrhea Treatment Oral Therapy , by Region USD Million (2021-2026)
  • Table 76. Carcinoid Syndrome Diarrhea Treatment Somatostatin Analog (SSA) Therapy , by Region USD Million (2021-2026)
  • Table 77. Carcinoid Syndrome Diarrhea Treatment Others , by Region USD Million (2021-2026)
  • Table 78. South America Carcinoid Syndrome Diarrhea Treatment, by Country USD Million (2021-2026)
  • Table 79. South America Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 80. South America Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 81. Brazil Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 82. Brazil Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 83. Argentina Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 84. Argentina Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 85. Rest of South America Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 86. Rest of South America Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 87. Asia Pacific Carcinoid Syndrome Diarrhea Treatment, by Country USD Million (2021-2026)
  • Table 88. Asia Pacific Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 89. Asia Pacific Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 90. China Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 91. China Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 92. Japan Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 93. Japan Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 94. India Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 95. India Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 96. South Korea Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 97. South Korea Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 98. Taiwan Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 99. Taiwan Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 100. Australia Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 101. Australia Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 102. Rest of Asia-Pacific Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 103. Rest of Asia-Pacific Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 104. Europe Carcinoid Syndrome Diarrhea Treatment, by Country USD Million (2021-2026)
  • Table 105. Europe Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 106. Europe Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 107. Germany Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 108. Germany Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 109. France Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 110. France Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 111. Italy Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 112. Italy Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 113. United Kingdom Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 114. United Kingdom Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 115. Netherlands Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 116. Netherlands Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 117. Rest of Europe Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 118. Rest of Europe Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 119. MEA Carcinoid Syndrome Diarrhea Treatment, by Country USD Million (2021-2026)
  • Table 120. MEA Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 121. MEA Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 122. Middle East Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 123. Middle East Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 124. Africa Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 125. Africa Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 126. North America Carcinoid Syndrome Diarrhea Treatment, by Country USD Million (2021-2026)
  • Table 127. North America Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 128. North America Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 129. United States Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 130. United States Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 131. Canada Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 132. Canada Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 133. Mexico Carcinoid Syndrome Diarrhea Treatment, by End User USD Million (2021-2026)
  • Table 134. Mexico Carcinoid Syndrome Diarrhea Treatment, by Treatment USD Million (2021-2026)
  • Table 135. Research Programs/Design for This Report
  • Table 136. Key Data Information from Secondary Sources
  • Table 137. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Carcinoid Syndrome Diarrhea Treatment: by Treatment USD Million (2015-2020)
  • Figure 5. South America Carcinoid Syndrome Diarrhea Treatment Share (%), by Country
  • Figure 6. Asia Pacific Carcinoid Syndrome Diarrhea Treatment Share (%), by Country
  • Figure 7. Europe Carcinoid Syndrome Diarrhea Treatment Share (%), by Country
  • Figure 8. MEA Carcinoid Syndrome Diarrhea Treatment Share (%), by Country
  • Figure 9. North America Carcinoid Syndrome Diarrhea Treatment Share (%), by Country
  • Figure 10. Global Carcinoid Syndrome Diarrhea Treatment share by Players 2020 (%)
  • Figure 11. Global Carcinoid Syndrome Diarrhea Treatment share by Players (Top 3) 2020(%)
  • Figure 12. Global Carcinoid Syndrome Diarrhea Treatment share by Players (Top 5) 2020(%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. Ipsen Biopharmaceuticals Inc. (France) Revenue, Net Income and Gross profit
  • Figure 15. Ipsen Biopharmaceuticals Inc. (France) Revenue: by Geography 2020
  • Figure 16. Lexicon Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Lexicon Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 20. Pharmascience Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 21. Pharmascience Inc. (Canada) Revenue: by Geography 2020
  • Figure 22. Omega Laboratories Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Omega Laboratories Ltd. (United States) Revenue: by Geography 2020
  • Figure 24. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 25. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 26. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 28. Sirtex Medical Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 29. Sirtex Medical Limited (Australia) Revenue: by Geography 2020
  • Figure 30. BTG International Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. BTG International Ltd. (United Kingdom) Revenue: by Geography 2020
  • Figure 32. Starpharma Holdings Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 33. Starpharma Holdings Limited (Australia) Revenue: by Geography 2020
  • Figure 34. Global Carcinoid Syndrome Diarrhea Treatment: by Treatment USD Million (2021-2026)
  • Figure 35. South America Carcinoid Syndrome Diarrhea Treatment Share (%), by Country
  • Figure 36. Asia Pacific Carcinoid Syndrome Diarrhea Treatment Share (%), by Country
  • Figure 37. Europe Carcinoid Syndrome Diarrhea Treatment Share (%), by Country
  • Figure 38. MEA Carcinoid Syndrome Diarrhea Treatment Share (%), by Country
  • Figure 39. North America Carcinoid Syndrome Diarrhea Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Ipsen Biopharmaceuticals Inc. (France)
  • Lexicon Pharmaceuticals, Inc. (United States)
  • Novartis International AG (Switzerland)
  • Pharmascience Inc. (Canada)
  • Omega Laboratories Ltd. (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Mylan N.V. (United States)
  • Sirtex Medical Limited (Australia)
  • BTG International Ltd. (United Kingdom)
  • Starpharma Holdings Limited (Australia)
Additional players considered in the study are as follows:
Mayo Clinic (United States) , Cleveland Clinic (United States)
Select User Access Type

Key Highlights of Report


Nov 2021 213 Pages 82 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Carcinoid Syndrome Diarrhea Treatment Market Quantitative research analysis
Global Carcinoid Syndrome Diarrhea Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Carcinoid Syndrome Diarrhea Treatment Market are Ipsen Biopharmaceuticals Inc. (France), Lexicon Pharmaceuticals, Inc. (United States), Novartis International AG (Switzerland), Pharmascience Inc. (Canada), Omega Laboratories Ltd. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (United States), Sirtex Medical Limited (Australia), BTG International Ltd. (United Kingdom) and Starpharma Holdings Limited (Australia) etc.
Carcinoid syndrome mostly occurs in a patients sufferings from metastatic neuroendocrine tumors. These are slow growing tumors and occur in the gastrointestinal tract result in chronic diarrhea. This causes weight loss, dehydration, malnutrition, and electrolyte imbalance which can be controlled by reducing the production of serotonin hormone. Increasing research to developed advanced treatments for Carcinoid syndrome Diarrhea expected to drive the market over the forecasted period.

Know More About Global Carcinoid Syndrome Diarrhea Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Cytomegalovirus Infection Comprehensive Study by Type (Cidofovir, Foscarnet, Valganciclovir, Ganciclovir), Application (Hospitals, Retail Pharmacies, Online Pharmacies), Infection (Retinitis, Pneumon...
$ 3750
Brain Disease Comprehensive Study by Disease Type (Neurodegenerative Diseases, Neurovascular Diseases, Mental Disorders, Traumatic Brain Injuries), Distribution Channel (Hospitals Pharmacy, Online Ph...
$ 3750
Plasma Fractionation Comprehensive Study by Type (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, Others), Application (Immunology, Hematology, Neurology, Others), End...
$ 3750
Endometriosis Therapies Comprehensive Study by Type (Hormonal Therapy (Oral Contraceptive Pills, Progestins), Hormone Replacement Therapy (GnRH Agonists, Luteinizing-hormone-releasing hormone recepto...
$ 3750
Thyroid Gland Disorder Treatment Comprehensive Study by Type (Medication, Surgery), Application (Men, Women), Diagnosis (Blood Tests, Imaging Tests, Physical Exams), Disorder Type (Hypothyroidism, Hy...
$ 3450
Lumbar Spine Fusion Comprehensive Study by Type (Anterior lumbar interbody fusion, Lateral lumbar interbody fusion, Posterior lumbar interbody fusion, Others), Application (Hospitals, Ambulatory Surg...
$ 3750